Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
-
BUSINESS Weber to Become CEO of Takeda in April
March 4, 2015
-
REGULATORY Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
-
BUSINESS Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
-
REGULATORY Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
-
ACADEMIA Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma
February 27, 2015
-
REGULATORY MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
-
BUSINESS Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
-
BUSINESS Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
-
REGULATORY Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
-
BUSINESS Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
-
REGULATORY Gilead’s Sofosbuvir Could Join NHI Price List in May If OK’ed by PAFSC Panel on March 5
February 20, 2015
-
REGULATORY Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
-
BUSINESS Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
-
REGULATORY Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
-
BUSINESS Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
-
BUSINESS Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
-
BUSINESS GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
-
BUSINESS Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
-
BUSINESS Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…